益生菌作用治疗非酒精性脂肪肝  

Effect of probiotics on non-alcoholic fatty liver disease

作　　者：姚晓敏[1] 曲均革[1] 林爱斌[1] 李宏伟[1] 

机构地区：[1]浙江医药高等专科学校药学系,宁波315100

出　　处：《国际药学研究杂志》2014年第5期548-551,558,共5页Journal of International Pharmaceutical Research

基　　金：浙江省教育厅科研项目(Y201122579);宁波市自然科学基金项目(2012A610245);浙江医药高等专科学校2011年度校级重点课题资助项目(ZPCSR2011001)

摘　　要：非酒精性脂肪肝(NAFLD)是一种比较常见的慢性肝病,其涵盖范围包括脂肪肝、脂肪性肝炎以及肝硬化。其发病率的增加与肥胖、2型糖尿病等密切相关。越来越多人体试验表明,肠道微生物菌群过度生长与NAFLD和非酒精性脂肪肝炎(NASH)有关。最近,已有很多研究表明益生菌在改善NAFLD方面有效,已被视为一种治疗NAFLD的新方式,但仍需大样本试验和较长周期的临床随访进行深入研究。鉴于此,本文主要对NAFLD以及益生菌治疗NAFLD的动物实验和临床试验研究进展情况进行综述,从而进一步为益生菌用于NAFLD的治疗提供借鉴。Non-alcoholic fatty liver disease（NAFLD）is a common chronic liver disease. It covers a spectrum of liver diseases that range from hepatic steatosis to steatohepatitis and cirrhosis. The increase in its prevalence is linked to obesity and type2 diabetes. More evidence shows a relation between overgrowth of gut microbiota with NAFLD and non-alcoholic steatohepatitis（NASH）. Recently,many studies indicate that probiotics have very good effcts on improving NAFLD. Probiotics have been seen as a new way of treating NAFLD. But probiotics as treatment of NAFLD still need substantiation through more trials with a larger sample size and with longer-term clinical follow-up. Therefore,the research progress in probiotics treatment on animal experiments and clinical trials in NAFLD is reviewed in order to further understand the role of probiotics treatment,and provide the basis for the treatment of NAFLD.

关 键 词：益生菌 非酒精性脂肪肝 非酒精性脂肪肝炎 肠道微生物 

分 类 号：R575.5[医药卫生—消化系统]